Table 1 Characteristics of patients 65 years and older, those younger than 65 years, and the entire cohort
Older patients (≥ 65) | Younger patients (< 65) | All patients | |
|---|---|---|---|
Patients (n) | 1583 | 3821 | 5404 |
Baseline measures | |||
Age in years at first metastatic trastuzumab dispensing, median (IQR) | 73 (68–78) | 52 (45–58) | 57 (48–66) |
< 35 | – | 138 (4%) | 138 (3%) |
35–44 | – | 760 (20%) | 760 (14%) |
45–54 | – | 1372 (36%) | 1372 (25%) |
55–64 | – | 1551 (40%) | 1551 (29%) |
65–74 | 937 (59%) | 937 (17%) | |
75–84 | 516 (33%) | – | 516 (10%) |
85+ | 130 (8%) | – | 130 (2%) |
Weight (kgs) at Herceptin Program enrolment, median (IQR) | 68 (59–77) | 70 (60–82) | 70 (60–80) |
Treatment qualification: | |||
HER2-positive by IHCa,c 3+, n | 871 (55%) | 2285 (60%) | 3156 (58%) |
HER2-positive by ISHb,c, n | 734 (46%) | 1615 (42%) | 2349 (43%) |
Previously treated with trastuzumab for EBC, n | 189 (12%) | 612 (16%) | 801 (15%) |
Number of medicines dispensed to treat comorbidity, n patients:d | |||
No medicines | 52 (3%) | – | – |
1–2 medicines | 73 (5%) | – | – |
3 or more medicines | 1458 (92%) | – | – |
Treatment with at least one cardiovascular medicine in the year prior to trastuzumab initiatione, n | 1047 (66%) | – | – |
Post-trastuzumab initiation measures | |||
Deaths, n | 1153 (73%) | 2622 (69%) | 3775 (70%) |
Median follow-up timef, years (IQR) | 5.7 (3.3–8.8) | 6.7 (3.9–10.3) | 6.4 (3.8–9.9) |